BCCA - Vancouver

Running trials

• Recruiting

  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

  NCT07341191· Phase 2· Source

• Recruiting

  STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

  NCT06880523· Phase 2· Source

• Recruiting

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· Phase 3· Source

• Recruiting

  LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

  NCT06623461· Phase 2· Source

• Recruiting

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· Phase 3· Source

• Recruiting

  Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

  NCT06182774· Phase 3· Source

• Recruiting

  Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

  NCT05601440· Phase 2· Source

• Recruiting

  Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

  NCT05371808· Source

• Recruiting

  Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  NCT05640999· Phase 2· Source

• Recruiting

  Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

  NCT05180097· Phase 2· Source

• Recruiting

  Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

  NCT04918186· Phase 2· Source

• Active, not recruiting

  Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

  NCT04161248· Early phase 1· Source

• Active, not recruiting

  Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

  NCT04093167· Phase 2/3· Source

• Recruiting

  Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

  NCT03297606· Phase 2· Source

• Recruiting

  Duration of Anti-PD-1 Therapy in Metastatic Melanoma

  NCT02821013· Phase 3· Source

• Active, not recruiting

  Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

  NCT02436707· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma2 recruiting
• Multiple myeloma2 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.